Research programme: dual phosphatidylinositol 3-kinase/mTOR inhibitors - Pfizer

Drug Profile

Research programme: dual phosphatidylinositol 3-kinase/mTOR inhibitors - Pfizer

Alternative Names: PF-04979064; PI3K inhibitors - Wyeth; PKI-402; TGX 221

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Wyeth
  • Developer Pfizer; Wyeth
  • Class 3-ring heterocyclic compounds; Naphthyridines; Pyrimidines; Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; MTOR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Arterial thrombosis; Cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA
  • 26 Aug 2010 Pharmacokinetics data from a preclinical trial in Cancer presented at the 240th American Chemical Society National Meeting (2340th-ACS-2010)
  • 19 Nov 2009 Pharmacodynamics data from a preclinical trial in Cancer presented at the 21st AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2009)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top